60 Degrees Pharmaceuticals, Inc. (SXTP) Price & Analysis

Compare

187 Followers

SXTP Stock Chart & Stats

$1.26

-$0.08(-5.71%)

At close: Jan 08 4:00 PM EST

$1.26

-$0.08(-5.71%)

Day’s Range― - ―

52-Week Range$1.22 - $12.45

Previous CloseN/A

Volume13.44M

Average Volume (3M)199.18K

Market Cap

$5.17M

Enterprise Value$11.16M

Total Cash (Recent Filing)$1.97M

Total Debt (Recent Filing)$154.25K

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Nov 13, 2025

EPS Estimate

-0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.16

Shares Outstanding4,104,469

10 Day Avg. Volume488,900

30 Day Avg. Volume199,179

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap2.16

Enterprise Value/Revenue11.62

Enterprise Value/Gross Profit40.22

Enterprise Value/Ebitda-1.46

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceProduct revenues showed a significant year-over-year increase, despite being supply-constrained.

Market OpportunitiesThe company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.

Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.

Bears Say

EarningsQ1 earnings per share were below estimates due to higher than forecast SG&A expenses.

Supply ConstraintsProduct revenues showed a significant year-over-year increase, despite being supply-constrained.

60 Degrees Pharmaceuticals, Inc. News

60 Degrees announces first patient completed regimen in babesiosis trial

60 Degrees Pharmaceuticals (SXTP) announced that the first patient to have completed the regimen in the Company’s trial...

22d ago

SXTP

60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial

60 Degrees Pharmaceuticals (SXTP) announced the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study....

28d ago

SXTP

60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis

60 Degrees Pharmaceuticals, Inc. (($SXTP)) announced an update on their ongoing clinical study. Study Overview: The B-FREE Chronic...

10d ago

SXTP

60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an update. On October 8, 2025, 60 Degrees Pharmaceuticals,...

27d ago

SXTP

60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential

An update from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) is now available. On September 9, 2025, 60...

2M ago

SXTP

60 Degrees Pharmaceuticals Enters New Sales Agreement

The latest update is out from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ). On September 3, 2025, 60...

2M ago

SXTP

60 Degrees selects Icahn School of Medicine as central site for Phase II study

60 Degrees Pharmaceuticals (SXTP) signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai...

3M ago

SXTP

60 Degrees Pharmaceuticals Reports Q2 2025 Earnings

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

SXTP

SXTP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

60 Degrees Pharmaceuticals, Inc. (SXTP) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall...

3M ago

SXTP

60 Degrees Pharmaceuticals Secures $5M in Recent Offering

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an announcement. On July 15, 2025, 60 Degrees Pharmaceuticals,...

4M ago

SXTP

60 Degrees Pharmaceuticals, Tulane University sign research agreement

60 Degrees Pharmaceuticals (SXTP) announced its entry into a sponsored research agreement with Tulane University to evaluate activity...

4M ago

SXTP

60 Degrees Pharmaceuticals prices 2.6M shares at $1.90 in public offering

60 Degrees Pharmaceuticals (SXTP) announced the pricing of a public offering of 2,631,578 shares of the Company’s common...

4M ago

SXTP

60 Degrees determines max commercial market size for ARAKODA at $245M annually

60 Degrees Pharmaceuticals (SXTP) announced it has determined the maximum size of the commercial market for ARAKODA for...

4M ago

SXTP

60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA

60 Degrees Pharmaceuticals (SXTP) announced that the company will conduct a gap analysis of its existing data prior...

4M ago

SXTP

SXTP FAQ

What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?

60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.22 and its highest was $12.45 in the past 12 months.

What is 60 Degrees Pharmaceuticals, Inc.’s market cap?

60 Degrees Pharmaceuticals, Inc.’s market cap is $5.17M.

When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?

60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 7 days.

How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?

60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.24 by $0.08.

Is 60 Degrees Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 60 Degrees Pharmaceuticals, Inc. pay dividends?

60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.

What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?

60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.46.

How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?

60 Degrees Pharmaceuticals, Inc. has 4,104,469 shares outstanding.

What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?

60 Degrees Pharmaceuticals, Inc. reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.24. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in SXTP

Company Description

60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company operates primarily in the healthcare sector, specializing in drug development aimed at addressing unmet medical needs. Its core products include novel pharmaceutical formulations and delivery systems designed to improve patient outcomes in the management of various infectious diseases.